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Abstract: Time affects facial aging by producing cellular and anatomical changes resulting in 
the consequential loss of soft tissue volume. With the advent of new technologies, the physician 
has the opportunity of addressing these changes with the utilization of dermal ﬁ  llers. Hyaluronic 
acid (HA) dermal ﬁ  llers are the most popular, non-permanent injectable materials available to 
physicians today for the correction of soft tissue defects of the face. This material provides 
an effective, non invasive, non surgical alternative for correction of the contour defects of the 
face due to its enormous ability to bind water and easiness of implantation. HA dermal ﬁ  llers 
are safe and effective. The baby-boomer generation, and their desire of turning back the clock 
while enjoying an active lifestyle, has expanded the popularity of these ﬁ  llers. In the US, there 
are currently eight HA dermal ﬁ  llers approved for commercialization by the Food and Drug 
Administration (FDA). This article reviews the innate properties of FDA-approved HA ﬁ  llers 
and provides an insight on future HA products and their utilization for the management of the 
aging face.
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Introduction
The aging phenomenon affects the human face by provoking an array of microscopic 
and macroscopic complex volumetric changes. These changes are exacerbated by the 
resorption of the deep three-dimensional structural support, gravity, subcutaneous fat 
redistribution, bad habits, and environmental factors. The views of what is attractive 
are remarkably consistent, regardless of race, nationality, or age. The esthetic concepts 
of beauty demand that certain curves, contours, dimensions, and ratios are fulﬁ  lled in 
order to create harmony and produce an attractive face.
In the past, surgical techniques have dominated the facial rejuvenation ﬁ  eld 
(de Maio 2004). The importance of volume restoration is now recognized, and in many 
cases has taken precedence over the two-dimensional lifting obtained when using the 
scalpel. Surgical procedures in some cases may even intensify the apparent loss of 
volume (Little 2000). Dermal ﬁ  llers achieve what no other procedure is capable of: 
they provide volume. Tissue volume augmentation via non-invasive procedures using 
soft tissue biodegradable ﬁ  llers can restore the youthful appearance to an aging face 
by ﬁ  lling out folds and improving ﬁ  ne lines and wrinkles, while proving safe and 
effective to both male and female patients across all ethnic groups.
Dermal ﬁ  llers have experienced an astounding demand in the US market since the 
introduction of bovine collagen-based dermal ﬁ  llers during the 1980s. The introduction 
of Restylane®, a hyaluronic acid (HA)-based ﬁ  ller at the end of 2003, has increased 
use of polymer ﬁ  llers by 700% (Matarasso et al 2006). Today, HA-based dermal ﬁ  llers 
are the fastest non-invasive esthetic procedure in the US, according to the American 
Society of Aesthetic Plastic Surgeons on February 24, 2006 (Wise and Greco 2006). 
While the list of injectable ﬁ  llers continues to expand with the use of different innovative Clinical Interventions in Aging 2008:3(1) 154
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compounds, HA ﬁ  llers still remain the most popular dermal 
ﬁ  ller agent for the management of facial aging (Lupo 2006). 
Crosslinked animal non-animal derived HA ﬁ  llers have been 
available for more than 18 years in the US and even longer 
in different countries around the world. These compounds 
are biocompatible (Fernandez-Cossio and Castaño-Oreja 
2006) and have the capacity to retain water at up to 1000 
times their volume (Johl and Burgett 2006).
Overall, the recent advances in injection techniques 
and a better understanding of facial aging can now provide 
experienced injectors with superior results when using cross-
linked hyaluronan dermal ﬁ  llers for facial remodeling. This 
article describes the utilization of HA dermal ﬁ  llers which 
are approved in the US by the Food and Drug Administration 
in the management of the aging face.
A brief history of HA
HA was ﬁ  rst discovered by two American scientists at 
Columbia University in New York City: Karl Meyer who is 
considered the father of glycosaminoglycan chemistry and 
his assistant John Palmer (Simoni et al 2002). In 1934 they 
were able to isolate this substance from bovine vitreous 
humor and later named it “hyalos” in combination with the 
uronic sugar also found in the substance. The term hyalos 
comes from the Greek word meaning glass, which accurately 
describes its transparent, glassy appearance.
HA was later used commercially for the ﬁ  rst time by 
Endre Balazs who applied for a patent to use this substance 
as a substitute for egg white in bakery products (Balazs and 
Denlinger 1989). Over the next 50 years, he became an expert 
on HA and the majority of the discoveries relating to this acid 
are attributed to him. During the last two decades, HA has 
been extensively used in eye surgery, wound repair, and for 
the treatment of arthritis joints via injection of the knees to 
aid movement due to its hydration and lubrication properties. 
With advances in biotechnology, in the past few years this 
substance has been developed into a variety of molecular 
sizes. Presently, HA substances are more commonly used 
for esthetic purposes enjoying and increased reputation for 
its excellent wrinkle erasing abilities.
Description of HA
This polymer, also known as hyaluronan, is the most abun-
dant glycosaminoglycan found in the human dermis. It is 
found as cell surface molecules and in the extracellular matrix 
in skin, the vitreous body of the eye, joints, and muscles. 
It is a ubiquitous component of all mammalian connec-
tive tissue and responsible for drawing water into the skin 
giving it volume while binding collagen and elastin ﬁ  bers 
into a supportive and protective matrix that gives the skin 
its structure. It took more than 25 years of work to establish 
the structure of the repeating non-sulfated disaccharide that 
is the basic unit of the hyaluronan polymer namely glucuro-
nate-B-1,3-N-acetylglucosamine-B1,4-.
HA is a naturally occurring biopolymer that exhibits no 
species or tissue speciﬁ  city. Its structure is identical if it is 
derived from bacterial cultures, animals, or humans. It is an 
essential component of the extracellular matrix of all adult 
animal tissues. Unmodiﬁ  ed, natural occurring hyaluronan 
is rapidly broken down by hyaluronidase and eliminated 
through the lymphatics and by the hepatic metabolism (Cole-
man and Grover 2006). In the skin, the half-life of unmodi-
ﬁ  ed, non-crosslinked HA is about 12 hours. Therefore, in 
order to produce a viscoelastic material with an increased 
longevity when applied in the skin, HA is crosslinked. Cur-
rently, there is an array of dermal ﬁ  llers available to the 
physician based on crosslinked HA technologies.
HA dermal ﬁ  llers
Scientists and physicians are constantly searching for the 
ideal dermal ﬁ  ller. This ideal ﬁ  ller should be safe and effec-
tive, biocompatible, non-immunogenic, easy to distribute 
and store, and should require no allergy testing. Moreover, 
it should be low cost, have an acceptable persistency. and be 
easy to remove if necessary. HA dermal ﬁ  llers have most of 
these ideal characteristics (Duranti et al 1998).
HA ﬁ  llers can easily be removed whenever the practitio-
ner considers necessary by injecting commercially available 
hyaluronidase (Vitrase®; ISTA Pharmaceuticals, CA, USA) 
into the concerned area (Soparkar et al 2004; Brody 2005; 
Goldberg and Fiaschetti 2006; Hirsch et al 2007). Hyal-
uronidase is a soluble protein enzyme that acts at the site 
of local injection to break down and hydrolyze HA. These 
important characteristics have made HA-based cosmetic 
injections the second most popular non-surgical procedure 
for women and the third most popular procedure for men in 
2006 (Winnington 2007).
Several HA ﬁ  llers are currently commercially available 
in the US (Table 1) for mid to deep dermal implantation 
for the correction of moderate to severe facial wrinkles and 
folds, such as nasolabial folds. Hylaform® was approved in 
April 2004 (Monheit 2004). This HA ﬁ  ller is composed of 
HA derived from avian sources and crosslinked with divi-
nyl sulfone (Narins and Bowman 2005). The utilization of 
Hylaform® dermal ﬁ  ller has substantially diminished since 
the approval of other HA ﬁ  llers. Captique® dermal ﬁ  ller is Clinical Interventions in Aging 2008:3(1) 155
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based on non-animal HA and was approved in December 
2004. Marketed by Allergan Inc., it will no longer be avail-
able after this year (pers comm, D. Moatazedi, Allergan, 
Inc., Nov 8, 2007).
Presently, the most widely used dermal ﬁ  ller in North 
America is Restylane®. Restylane® was FDA-approved in 
December of 2003. Since 2003, with the results from the pivotal 
multicenter, double-blind clinical study, it has been proven that 
Restylane® is safe and effective in the treatment of nasolabial 
folds (Narins et al 2003). Perlane®, a more viscous version of 
Restylane®, was FDA-approved in 2007. Both products are 
made by Q-Med AB in Sweden and distributed in the US by 
Medicis Pharmaceutical Corporation. They are based on “non-
animal stabilized hyaluronic acid” (NASHA) and produced 
from cultures of Streptococcus equi via a proprietary process 
crosslinked with 1,4-butanediol diglycidyl ether (BDDE) giving 
a ﬁ  nal concentration of 20 mg/mL. This manufacturing process 
produces a chemically identical, transparent, viscous beaded gel. 
Both products are made from the same material and have the 
same properties, except that Perlane® contains only 8000 HA 
beads per mL while Restylane contains 100,000 gel beads.
Restylane® and Perlane® degradation is isovolemic, 
meaning, it retains most of its initial ﬁ  ller volume throughout 
the degradation phase. The beneﬁ  t produced by these ﬁ  llers 
is via a volume effect and by attracting and binding water. 
When fully degraded, it is absorbed without any ﬁ  brosis or 
remaining implant product. Metabolism by-products are 
water and carbon dioxide. Recent histopathological research 
with Restylane® has shown that it also stimulates neocolla-
genesis (Wang et al 2007).
The new HA dermal ﬁ  llers, Juvéderm™ Ultra and Juvé-
derm™ Ultra Plus injectable gels, are distributed by Allergan, 
Inc. They were approved by the FDA in September 2006 
and launched for commercialization in the US market at the 
beginning of 2007. Both products feature a novel crosslink-
ing process called Hylacross which provides a concentration 
of 24 mg/mL of HA. Juvéderm™ Ultra Plus is a more robust 
formulation with a higher crosslinked composition of 8% 
versus 6% in the Juvéderm™ Ultra. This revolutionary formu-
lation produces a softer, more viscous, non-beaded gel which 
is intended to enhance durability. A prospective double-blind, 
randomized, within-subject controlled, multi-center clinical 
trial comparing Juvéderm™ Ultra or Juvéderm™ Ultra Plus 
to bovine collagen have shown an increased persistence for 
the HA products (Package Insert Juvéderm Ultra L040-04 
12/06; Juvéderm Ultra Plus L041-04 12/06). Throughout 
the 24-week study period, Juvéderm™ Ultra and Juvéderm™ 
Ultra Plus injectable gel provided a clinically and statistically 
signiﬁ  cant improvement in nasolabial severity. Based on new 
clinical data demonstrating that the effects with a single treat-
ment of either formulations may last for up to 12 months, the 
FDA have granted a label extension for Juvéderm™ Ultra and 
Juvéderm™ Ultra Plus in June, 2007 (Allergan, Inc. 2007).
Elevess™ is the latest HA approved by the FDA, in July 
2007. The product, manufactured by Anika Therapeutics, 
MA, USA, is based on chemically modiﬁ  ed non-animal HA 
proprietary technology which incorporates 0.3% lidocaine 
hydrochloride as a component of the treatment syringe. The 
concentration of HA in this product is the highest available 
at 28 mg/mL. Elevess™ crosslinker is p-phenylene bisetheyl 
carbodimide (BCDI). At time of publication, this product is 
not commercially available.
All of these HA ﬁ  llers available in the US are approved for 
the cosmetic improvement of the nasolabial fold; however, 
used off-label, injectable HA dermal ﬁ  llers are useful for 
restoring volume to localized areas such as the cheeks, as 
well as reduction of the oral commissures, marionette lines, 
forehead lines, temple areas, tear trough, jowls, and lips.
The HA dermal ﬁ  llers on the horizon are Puragen, Pura-
gen Plus, Prevelle, Prevelle Plus, Belotero, and Teosyal 
family of products (Table 2). Puragen and Puragen plus 
are based on double crosslinked (DXL™) technology with 
non-animal HA chains. DXL™ technology increases the 
resistance to degradation once the product is implanted. 
Puragen Plus product will incorporate lidocaine for pain 
management. Prevelle and Prevelle Plus will be less robust 
formulationa and according to the manufacturer will produce 
Table 1 FDA-approved hyaluronic acid ﬁ  llers





Juvederm Ultra Allergan, Inc
Juvederm Ultra Plus Allergan, Inc
Perlane Medicis
Elevess Anika therapeutics
Table 2 Hyaluronic acid dermal ﬁ  llers to come and not yet 
available in the US
Product Company
Teosyal Teoxane, Switzerland
Puragen Plus Mentor, CA, USA
Prevelle Mentor, CA, USA
Belotero Merz pharmaceuticals, NC, USAClinical Interventions in Aging 2008:3(1) 156
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less immediate post-injection adverse events. These four 
products are manufactured by Mentor Corporation, CA, 
USA. Belotero, manufactured by Anteis SA, Geneva, 
Switzerland and distributed by Merz Pharmaceutical LLC, 
is also based on double crosslinked technology called 
Cohesive Polydensiﬁ  ed Matrix (CPM) with BDDE and 
nonanimal HA chains. Teosyal family of products consists 
of 7 formulations based on monophasic, non-animal HA, 
crosslinked with BDDE.
Having an expanded armamentum physicians have now 
several choices of HA dermal ﬁ  llers. It is important to keep 
in mind that not all HA ﬁ  llers are created equal. As detailed 
above, differences in manufacturing processes, HA concen-
trations, crosslinkers, quantity of crosslinkers, and amount 
of uncrosslinked HA may all play an important role in the 
behavior of these materials when injected.
There are several techniques that can be utilized for the 
facial implantation of HA dermal ﬁ  llers. Linear threading, 
serial puncture, fanning, and cross-hatching, or a combination 
of all four has been successfully used for the management 
of the aging face with HA dermal ﬁ  llers. As with all inject-
able procedures, the patient desires and expectations should 
be carefully reviewed (Kelly 2007). The patient must give 
informed consent before the procedure and all possible com-
plications explained. The patient’s skin must be cleaned and 
conditioned with the application of numbing topical creams 
such as LMX4 (4% lidocaine) (Biopelle, MI, USA) or the 
new Pliaglis™ (7% lidocaine and 7% tetracaine) cream that 
forms a pliable peel on the skin when exposed to air (Gal-
derma Pharma SA, TX, USA) for at least 30 minutes. Some 
practitioners prefer to use regional nerve blocks (Rao et al 
2005; Matarasso et al 2006).
Once the HA ﬁ  ller is injected, it might be lightly mas-
saged to conform to the contour of the surrounding tissues. 
It is important to remember that these ﬁ  llers are hygroscopic 
and may increase correction up to 15% after injection (Mon-
heit 2006). It is good clinical practice to get an understanding 
of the patient’s realistic goals and evaluate whether or not HA 
ﬁ  llers can fulﬁ  ll their desires during consultation. Conceptu-
ally, the aging face can be divided into upper, middle, and 
lower thirds. Using this approach, we will discuss the clinical 
strategies for addressing each of these facial regions.
Upper face (Table 3)
Glabellar lines
The symmetrical lines between the eyebrows that develop 
by the prolonged muscular action of the corrugator supercilii 
and procerus muscles respond extremely well to botulinum 
toxin therapy (Carruthers and Carruthers 2003). However, 
in cases where the patient has deep glabellar furrows, HA 
ﬁ  llers can be used depending on the severity of the defect. 
Botulinum toxins and dermal ﬁ  llers combined produce the 
best results for the treatment of this area. It is important that 
implantation of the HA ﬁ  ller is completed without overcor-
rection. Moreover, this area is very sensitive to occlusion of 
blood vessels; therefore, ﬁ  llers must be applied superﬁ  cially 
to minimize the risk of cutaneous necrosis.
Forehead lines
Forehead horizontal lines are the resultant defect produced by 
the dynamic action of the frontalis muscles (Stennert 1994). 
Wrinkles in this area could be dynamic or non-dynamic. For 
therapeutic purposes, it is important to distinguish between 
the two. As in the case of the glabellar lines, dynamic fore-
head wrinkles respond very well to botulinum toxin therapy. 
Non-dynamic forehead wrinkles result mostly from the vol-
ume loss of the underlying tissue. Injected superﬁ  cially via 
serial puncture technique without overcorrection, HA ﬁ  llers 
can provide good esthetic results.
Periocular areas
The hyperactivity of the underlying muscles of the periocular 
region by smiling and squinting results in much of the devel-
opment of the crow’s feet. Most of these wrinkles respond 
best to botulinum toxin therapy. Deeper periocular wrinkles 
qualify and respond well to treatment with HA dermal ﬁ  llers 
using retrograde linear threading or serial puncture technique 
via a 32-gauge needle. The delicate nature of the skin in this 
area is the primary concern. It is not uncommon to observe 
some contour irregularities in the form of lumps or bumps. 
In addition, due to the rich subdermal vascular plexus, this 
area is very prone to signiﬁ  cant bruising.
Facial aging affecting fat atrophy of the temple area 
responds well to HA treatment. Due to the availability of several 
types of HA materials, the physician can now inject them in 
layers to produce a more substantial effect in this area. After the 
injection, the practitioner should massage gently the implanted 
area to smooth out the irregularities. Ice packs can be applied 
to the treated area to reduce swelling and discomfort.




Periocular Perlane and/or RestylaneClinical Interventions in Aging 2008:3(1) 157
Hyaluronic acid gel ﬁ  llers for facial aging
The facial aging process results in dropping and receding 
brows. The injection of HA ﬁ  llers has become very popular 
to elevate the brow and produce a younger facial expression. 
Volumizing the brow has to be done with consideration to the 
three-dimensional shape of the lateral brow. The end result 
is a desirable arching contour. The ﬁ  ller material is injected 
just below the cilia and implanted using the anterograde 
technique as the needle is pushed forward across the brow 
to the notch. Due to the malleable properties of these ﬁ  llers, 
the material can be contoured by pressing it along the brow 
between the thumb and the index ﬁ  ngers. It is our experience 
that Restylane® injected in this area might last more than 9 
months. Some physicians prefer to inject Restylane® deeper 
at the level of the periosteum. Longer tenderness in the treated 
area has been reported when this technique is use with this 
material (Matarasso et al 2006). Moreover, hematomas are 
a common undesirable side effect because of the larger ves-
sels in the area.
Midface (Table 4)
Facial aging consistently produces increasing prominence 
of the midface, hollow eyes, nasolabial folds, cheeks, lips, 
jowls, and chin.
Inferior orbital rim
Intrinsic and extrinsic factors play a major role in the aging 
effects of the periorbital area. Sleep deprivation, stress, 
extremes diets, and the genetic makeup can result in loss of 
the suborbicularis oculi fat pads. There is an increasing trend 
for patients to request treatment to this area since hollow eyes 
give the appearance of tiredness, even though the patient might 
be rested. HA ﬁ  llers do provide a refreshed facial expression 
when properly injected. Care should be taken not to inject the 
material too superﬁ  cially to avoid the formation of papules that 
can be easily observed since the skin in this area is very thin 
and delicate. HA is injected into the deep cutaneous tissues 
using the serial puncture technique or threading technique, 
injecting the product as the needle is withdrawn (Kane 2007). 
Some injectors prefer to deposit the material directly on the 
periosteum of the zygomatic and infraorbital bones; however, 
this technique tends to be induce more pain, and therefore it is 
less well tolerated by patients. Others prefer to deposit the ﬁ  ller 
intraorally. Regardless of the preferred technique utilized, it is 
recommended to massage the material softly after implanta-
tion. Due to the high vascularity present in this area, bruising 
is a major side effect when ﬁ  llers are injected into the inferior 
orbital rim. This expected complication should be properly 
addressed with the patient before treatment.
Cheeks and nasolabial folds
It is now recognized that volumizing the cheeks generates 
a signiﬁ  cant rejuvenation effect. With the passage of time, 
the facial triangle of a young face where the apex is at the 
chin gets reversed, and the volume that was once on the mid-
face moves down reversing the orientation of this triangle of 
youth. Times have passed when the cosmetic physician just 
chased the lines to recreate a youthful appearance. Presently, 
the cheek and malar areas are rejuvenated by injecting HA 
dermal ﬁ  llers, especially the most robust formulations such 
as Perlane® or Juvéderm™ Ultra Plus via serial puncture or 
linear threading techniques in the lower dermis as the needle 
is withdrawn while full correction is attempted. Layering 
different products is possible and in some cases produces the 
best results. By volumizing the cheek and the lost malar fat 
pads, not only is the nasolabial fold corrected but, moreover, 
an overall facial rejuvenation is achieved. The face looks 
younger and plumped. It is important not to over correct and 
not to inject too superﬁ  cially to avoid the creation of visible 
lumps. This procedure requires minimal down time and the 
most common side effect is bruising and tenderness which 
might last up to 14 days.
Lower face (Table 5)
Perioral area
Fine lines develop on the perioral region due to repetitive 
motion of the underlying musculature when pursing the lips 
such as when smoking or sucking through a straw. These ﬁ  ne 
lines can be treated by injecting HA ﬁ  llers with a 33-gauge 
needle. This techniques allows for breaking up the HA gel, 
especially in the case of Restylane® into a ﬁ  ner material 
more suitable for the treatment of these ﬁ  ne lines without 
overcorrection.
Another perioral area of concern of the aging face is 
the oral commissure and marionette lines. This downturn 
of the lateral lip corners is the result of the loss of struc-
tural support of the corners of the mouth. These changes 
result in the appearance of sadness and old age. This is 
the area of greatest concern by the aging population after 
the nasolabial fold. The oral commissures and marionette 
lines can be treated safely and effectively with a combi-
nation of HA ﬁ  llers by using the serial puncture and/or 
Table 4 Preferred hyaluronic acid products for the midface
Area
Cheeks Perlane
Nasolabial folds Juvéderm Ultra and/or RestylaneClinical Interventions in Aging 2008:3(1) 158
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cross-hatching techniques while elevating the affected 
area with the non-injecting hand before implantation of 
the material. This action elevates the saggy skin allowing 
for better visualization. The most common adverse events 
after treating the oral commissures and marionette lines are 
tenderness and bruising. A more serious side effect is tissue 
necrosis. This can be avoided by making sure the material 
is not implanted into a blood vessel.
Lips
One of the most requested areas for tissue augmentation 
in young and old patients alike are the lips. Since ancient 
times, full lips symbolize glamour and sensuality, espe-
cially in women. Lips are a key esthetic feature of the 
lower face. Lips are also affected by the aging process. 
Lips lose their fullness, deﬁ  nition, and therefore their 
anatomical shape and expected beauty ratio proportions. 
They become narrow, pale, and ﬂ  at. HAs are ideal ﬁ  llers 
to replenish the volume lost and re-establish the pleasing 
esthetic look of well proportioned and voluminous lips. It 
is important to consult the patient carefully to ﬁ  nd out if 
she/he wants to restore their lips to their former appearance, 
or if they want a different, more sumptuous look (Bousquet 
and Agerup 1999).
Serial puncture anterograde technique is used to redeﬁ  ne 
the vermillion border producing a natural contour of the lip. 
For replenishing the volume of the mucosa of the lip, the 
robust HA ﬁ  ller formulations can be utilized using retrograde 
serial puncture techniques. The most robust formulations 
provide for longer lasting results (Brandt and Cazzaniga 
2007).
Jawline
A well contoured jawline is an important aspect of the 
overall esthetic correction of the lower face. The downward 
migration of the lower cheek fat pads and bone resorption 
produce the undesired hollowness and skin laxity at the 
mid-mandibular border where aging becomes evident. HA 
ﬁ  llers are excellent materials to reshape and contour the atro-
phied jowls by lifting and tightening the senescent sagging 
cutaneous tissues to create a younger-looking appearance.
HA dermal ﬁ  llers are injected in this area by serial 
puncture and linear threading techniques. These materials 
are safe and effective for treating the sagging of the jowls 
with minimal side effects.
Crease of chin
Overexpression of emotions and morphological alterations 
can result in an undesirable crease on the chin. Because the 
loss of dermal collagen and subcutaneous fat pads add to 
this insult, patients ﬁ  nd this defect very unattractive. HA 
dermal ﬁ  llers provide a successful and lasting treatment 
effect to this area. Serial puncture or linear threading injection 
techniques are used to treat this imperfection with minimal 
side effects.
Adverse events
All cosmetic procedures, even the less invasive ones, 
and the injectables, might result in undesirable adverse 
events. Therefore, HA-based dermal ﬁ  llers are not devoid 
of inducing complications. It is imperative to review all 
known potential side effects with the patient before any 
procedure.
The most common localized side effects encountered 
after treatments with HA dermal fillers are temporary 
pain, induration, bruising, tenderness, itching, edema, and 
erythema at the injection site (Lowe et al 2005). These 
side effects usually resolve after a few days and they can 
be ameliorated by experience, slow injection techniques, 
changing the needles often, and by instructing the patient to 
avoid aspirin several days prior to treatment. There have been 
reports of hypersensitivity reactions ranging from 0.0005% 
to 0.42% (Brown and Frank 2003; Hönig et al 2003) and, 
in rare cases, necrosis or embolization might occur (Schanz 
et al 2002; Hirsch et al 2007). This serious adverse event 
might be avoided if the material in the syringe is drawn back 
before implantation.
Conclusion
Esthetic facial volume restoration along with all other 
components of the aging face must be adequately addressed 
to successfully rejuvenate the face. The safe and effective 
track record of HA dermal ﬁ  llers makes them currently the 
most popular ﬁ  lling material. This popularity will continue 
to increase as the aging population searches for viable 
options to correct the signs of aging without surgery. The 
utilization of these ﬁ  llers by trained professionals provides 
an effective and safe therapy for the management of the 
aging face.
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